Recognized for excellence in single-cell microfluidics, Sphere Bio takes top honors at the 2025 GHP Biotechnology & Lifesciences Awards
Biotechnology & Lifesciences Award 2025 — Global Health & Pharma
Cambridge, UK [15 April, 2025]: Sphere Bio, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, has been named Best Droplet Microfluidic Technology Company 2025 at the Biotechnology & Lifesciences Awards, presented by Global Health & Pharma (GHP).
The annual GHP awards celebrate companies that are transforming life sciences through innovation, impact, and technical excellence. This year’s winners span the full spectrum of biotechnology — and Sphere Bio’s recognition stands as a testament to its commitment to advancing single-cell discovery through picodroplet microfluidics.
This strategic scale-up enhances Sphere Bio’s ability to provide localized product support and increase adoption of its growing technology portfolio, including the recently launched Cyto-Mine® Chroma platform and new assay offerings. The investment in new partnerships reflects the Company’s long-term commitment to serving the region and supporting local customers with in-depth expertise.
At Sphere Bio, we believe that working at the tiniest scale can lead to the biggest breakthroughs. This award is a reflection of our team’s dedication — and of the incredible scientists we partner with every day,”
— Claire Cox, Global Marketing Director, Sphere Bio
Sphere Bio’s proprietary microfluidic platform, including its flagship Cyto-Mine® technology, enables rapid, high-throughput screening of up to 40 million cells per day. The system combines cell encapsulation, manipulation, analysis, and isolation into one streamlined workflow — helping scientists in biopharma, cell therapy, and synthetic biology unlock new possibilities with greater speed and confidence.
Kaven Cooper, Awards Coordinator at GHP, praised this year’s winners for driving a “healthier, brighter, and more informed future” through their contributions to science and medicine. Sphere Bio is proud to be counted among them.
This award further validates Sphere Bio’s mission: to ease the journey to discovery by delivering tools that are powerful, precise, and refreshingly easy to use.
To view the full list of winners, visit: https://ghpnews.digital/awards/biotechnology-awards
For more information contact:
Dr Claire Cox
Sphere Bio Ltd.
Tel: +44 (0)7365 209 441
Email: claire.cox@spherebio.com
About Sphere Bio
Sphere Bio develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Bio’s proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally.
Sphere Bio is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.
For more information contact:
